U.S.-listed shares of Danish drugmaker Novo Nordisk rise 6% premarket.
The UK health regulator has approved a higher 7.2 mg weekly dose of Novo's Wegovy for obesity patients.
Newer studies found the 7.2 mg dose can achieve around 20% weight loss.
The new dose is given as three separate injections and exceeds the previous 2.4 mg limit.
NVO fell ~42% in 2025.